Sbir phase I topic #446 - development of senotherapeutic agents for cancer treatment
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00038
- Awardee
-
Atux Iskay Group LLC UEI C7JPQ5F3UUH7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $400,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20231 · Posted Jul 20, 2022
- Contract value 100% obligated
- $400,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Plainsboro Township, NJ 08536, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $400,000 |
About this award
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Atux Iskay Group LLC, a for-profit limited liability company. The $400,000 firm-fixed price contract will support the development of senotherapeutic agents for cancer treatment. This is a total small business set-aside contract, with work to be performed primarily in Plainsboro Township, New Jersey. The contract stems from a pre-solicitation notice seeking SBIR proposals to support the missions of NIH and CDC through research and development in various areas, including cancer treatment. Atux Iskay Group LLC is a company that specializes in developing innovative therapeutic technologies, with a focus on protein phosphatase 2A (PP2A) activation as a potential approach for treating conditions like neuroblastoma, medulloblastoma, Alzheimer's disease, and pulmonary fibrosis.
Quick answers
Who was awarded contract 75N91023C00038?
75N91023C00038 was awarded to Atux Iskay Group LLC by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023C00038 worth?
The government has obligated $400,000 on 75N91023C00038.
Was contract 75N91023C00038 competed?
The extent of competition for 75N91023C00038 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award